ArticleInfection and immunity1999
Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 104 citations in OpenAlex.
- Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.PloS one · 2011Trial
- Repeated Bordetella pertussis Infections Are Required to Reprogram Acellular Pertussis Vaccine-Primed Host Responses in the Baboon Model.The Journal of infectious diseases · 2024Article
- Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.BMC immunology · 2021Article
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Maternal Immunization: Nature Meets Nurture.Frontiers in microbiology · 2020Review
- Article
- Neonatal Immunity toJournal of immunology research · 2019Review
- Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.Frontiers in immunology · 2019Article
- What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.Cold Spring Harbor perspectives in biology · 2017Review
- Article
- Long time immunogenicity of measles vaccine in the vaccination era: An open question.Human vaccines & immunotherapeutics · 2017Article
- Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.Immunogenetics · 2016Article
- Rediscovering Pertussis.Frontiers in pediatrics · 2016Review
- Waning and aging of cellular immunity to Bordetella pertussis.Pathogens and disease · 2015Review
- Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.Pathogens and disease · 2015Review
- Roads to the development of improved pertussis vaccines paved by immunology.Pathogens and disease · 2015Review
- Characterization of co-purified acellular pertussis vaccines.Human vaccines & immunotherapeutics · 2015Article
- Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.Clinical and vaccine immunology : CVI · 2014Article
- Article
- Prediction of virulence factors using bioinformatics approaches.Methods in molecular biology (Clifton, N.J.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cell-mediated immune (CMI) responses to Bordetella pertussis antigens (pertussis toxin [PT], pertactin [PRN], and filamentous hemagglutinin [FHA]) were assessed in 48-month-old recipients of acellular pertussis [aP] vaccines (either from Chiron-Biocine [aP-CB] or from SmithKline Beecham [aP-SB]) and compared to CMI responses to the same antigens at 7 months of age, i.e., 1 month after completion of the primary immunization cycle. None of the children enrolled in this study received any booster of pertussis vaccines or was affected by pertussis during the whole follow-up period. Overall, around 75% of 4-year-old children showed a CMI-positive response to at least one B. pertussis antigen, independently of the type of aP vaccine received, and the proportion of CMI responders were at least equal at 48 and 7 months of age. However, longitudinal examination of individual responses showed that from 20 (against PT) to 37% (against FHA) of CMI responders after primary immunization became negative at 48 months of age. This loss was more than compensated for by conversion to positive CMI responses, ranging from 36% against FHA to 69% against PRN, in other children who were CMI negative at 7 months of age. In 60 to 80% of these CMI converters, a lack of decline or even marked elevation of antibody (Ab) titers against B. pertussis antigens also occurred between 20 and 48 months of age. In particular, the frequency of seropositivity to PRN and FHA (but not to PT) was roughly three times higher in CMI converters than in nonconverters. The acquisition of CMI response to B. pertussis antigens in 48-month-old children was not associated with a greater frequency of coughing episodes lasting >/=7 days and was characterized by a prevalent type 1 cytokine profile, with high gamma interferon and low or no production of interleukin-5, reminiscent of cytokine patterns following immunization with whole-cell pertussis vaccine or natural infection. Our data imply that vaccination-induced systemic CMI may wane by 4 years of age but may be acquired or naturally boosted by symptomless or minor clinical infection by B. pertussis. This might explain, at least in part, the persistence of protection against typical pertussis in aP vaccine recipients despite a substantial waning of both Ab and CMI responses induced by the primary immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.